Want to see JP:4577 full AI Analyst Report?
Daito Pharmaceutical Co., Ltd. (4577) AI Stock Analysis
Daito Pharmaceutical Co., Ltd.
(TSE/TYO:4577)
Daito Pharmaceutical earns a solid overall score of 75, driven primarily by its exceptionally strong balance sheet, improved free cash flow generation, and attractive valuation. Its 3.03% dividend yield and conservative leverage provide a substantial margin of safety for investors. Short-term technical indicators lean slightly bullish, though top-line revenue stagnation remains the most notable risk factor moving forward.
Daito Pharmaceutical Co., Ltd. (4577) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 37.39B
- Dividend Yield
- 3.02%
- Average Volume (3M)
- 78.13K
- Price to Earnings (P/E)
- 12.2
- Beta (1Y)
- 0.22
- Revenue Growth
- -2.83%
- EPS Growth
- 65.69%
- Country
- Japan
- Employees
- 1,085
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Daito Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both presc...
Daito Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Daito Pharmaceutical displays a highly stable financial foundation characterized by a conservative debt-to-equity ratio of 0.17 and a robust turnaround to positive free cash flow. While the bottom-line profit margins have improved significantly, the top-line revenue growth remains a primary weakness.
Income Statement
68PositiveBalance Sheet
88Very PositiveCash Flow
82Very Positive| Breakdown | TTM | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.53B | 50.65B | 50.64B | 46.90B | 45.10B | 43.46B |
| Gross Profit | 9.53B | 9.90B | 8.47B | 9.67B | 10.15B | 11.31B |
| EBITDA | 7.05B | 8.02B | 7.41B | 7.92B | 8.96B | 10.04B |
| Net Income | 3.17B | 3.16B | 1.91B | 3.29B | 3.60B | 4.67B |
Balance Sheet | ||||||
| Total Assets | 71.65B | 73.29B | 78.00B | 77.71B | 70.55B | 64.94B |
| Cash, Cash Equivalents and Short-Term Investments | 1.69B | 954.00M | 2.21B | 2.73B | 3.61B | 4.38B |
| Total Debt | 8.45B | 9.29B | 11.88B | 8.72B | 4.89B | 3.44B |
| Total Liabilities | 19.16B | 20.35B | 25.93B | 25.44B | 19.58B | 17.26B |
| Stockholders Equity | 52.42B | 52.89B | 52.00B | 52.07B | 50.67B | 47.31B |
Cash Flow | ||||||
| Free Cash Flow | 5.53B | 5.53B | -957.00M | -1.04B | -1.35B | -257.00M |
| Operating Cash Flow | 9.38B | 9.38B | 5.90B | 5.18B | 4.16B | 4.37B |
| Investing Cash Flow | -4.39B | -4.39B | -7.37B | -5.93B | -5.57B | -4.33B |
| Financing Cash Flow | -6.29B | -6.29B | 1.00B | -183.00M | 616.00M | 921.00M |
Daito Pharmaceutical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4577, the sentiment is Positive. The current price of 1321.00 is below the 20-day moving average (MA) of 1331.25, below the 50-day MA of 1325.80, and above the 200-day MA of 1310.65, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 48.94 is Neutral, neither overbought nor oversold. The STOCH value of 22.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4577.
Daito Pharmaceutical Co., Ltd. Peers Comparison
Overall Rating
- JP:457775Outperform
JP:453468Neutral
JP:488666Neutral
JP:455460Neutral
JP:456952Neutral
JP:453946.5Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4577 | 75Outperform | JPY 38.17B | 12.15 | ― | 3.02% | -2.83% | 65.69% |
| JP:4534 | 68Neutral | JPY 111.78B | 12.67 | 6.64% | 2.51% | 14.72% | 52.55% |
| JP:4886 | 66Neutral | JPY 52.85B | 11.96 | ― | 3.27% | ― | -7.20% |
| JP:4554 | 60Neutral | JPY 48.76B | 15.72 | 6.04% | 2.15% | 20.36% | -5.53% |
| JP:4569 | 52Neutral | JPY 58.17B | 29.23 | ― | 4.25% | -4.71% | -78.91% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4539 | 47Neutral | JPY 5.47B | -44.12 | ― | 3.30% | 0.31% | -194.72% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4577 | Daito Pharmaceutical Co., Ltd. | 1323.00 | 118.19 | 9.81% | |
| JP:4554 | Fuji Pharma Co., Ltd. | 1870.00 | 328.98 | 21.35% | |
| JP:4534 | Mochida Pharmaceutical Co., Ltd. | 3285.00 | 406.97 | 14.14% | |
| JP:4539 | Nippon Chemiphar Co., Ltd. | 1515.00 | -100.80 | -6.24% | |
| JP:4569 | KYORIN Pharmaceutical Co.,Ltd. | 1105.00 | -256.96 | -18.87% | |
| JP:4886 | ASKA Pharmaceutical Holdings Co., Ltd. | 1986.00 | -47.74 | -2.35% |
Daito Pharmaceutical Co., Ltd. Corporate Events
Daito and Partners Launch JV to Acquire KYORIN Generic Drug Unit
Daito Pharmaceutical has joined with Meiji Seika Pharma and the Development Bank of Japan to form Pharmatech Co-creation Platform, Inc., a new joint venture that will acquire KYORIN Pharmaceutical’s consolidated subsidiary KYORIN Rimedio, exclu...
Daito Pharmaceutical Completes ¥605 Million Share Buyback to Boost Capital Efficiency
Daito Pharmaceutical has completed a share buyback under its Medium-Term Management Plan as part of efforts to enhance shareholder returns and improve capital efficiency. The company acquired 484,000 shares, equivalent to about 1.7% of its outstandin...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 11, 2026